Navigation Links
Catalent to Discuss the Future of Cell and Gene Therapy Manufacturing at World Orphan Drug Congress Europe
Date:11/5/2019

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced it will present at the upcoming World Orphan Drug Congress Europe, being held at Hotel Sofia, Barcelona, Spain on Nov. 12 – 14, 2019.

On Wednesday, Nov. 13 at 3:20 p.m., Philip Wills, Ph.D., Chief Commercial Officer, Paragon Gene Therapy (part of Catalent Biologics) will present “Capacity Crunch? The Future of Manufacturing Within Cell & Gene Therapy” as part of the manufacturing track. Dr. Wills’ presentation will highlight the challenges that the gene therapy sector faces in scale-up and manufacturing, driven by the rising numbers of clinical trials and FDA approvals, coupled with low product yields and rising treatment costs. These factors have led to an increased demand for process expertise and manufacturing capacity, and Dr. Wills will address the capacity limitations and discuss the future of cell and gene therapy manufacturing.

Also, on Wednesday, at 2:20 p.m., Stephen Tindal, Director, Science & Technology and Gavin Yates, Program Director, Clinical Supply Services and Drug Product Technologies Integrations, will discuss the benefits of contracting with a single, integrated provider in their presentation, “Next Exit, Success: Get from Concept to Clinic Faster on the Product Development Superhighway.” In the presentation, Mr. Tindal and Mr. Yates will highlight opportunities to streamline and shorten product development timelines.

Dr. Wills has almost two decades of contract manufacturing experience, primarily focused in viral vectors and other complex biologics. He joined Paragon in 2002 where he has since held positions of increasing scope and responsibility, including as Principal Scientist and Vice President of Business Development. He received a bachelor’s degree in chemistry from John Hopkins University, Baltimore, Maryland, and a doctorate in pharmacology from University of Maryland Medical School, Maryland.

Mr. Tindal has worked in softgel R&D for more than 30 years and has broad expertise in this technology. He specializes in root cause investigation, technology innovation, gelatin innovation, and plays a key role in customer liaison and supporting business development. Mr. Tindal holds a bachelor’s degree in chemistry and analytical science from Loughborough University, U.K.

Mr. Yates has more than 15 years’ experience in the pharmaceutical industry. His areas of expertise include project management, packaging and labeling, operational activity, supply chain management and key performance indicator (KPI) analysis. He received his bachelor’s degree in biological sciences from University of Birmingham, U.K.

For more information, visit https://www.catalent.com/index.php/news-events/events/World-Orphan-Drug-Congress-Europe.

To arrange a meeting with any of the attending Catalent experts at the event, contact Richard Kerns at NEPR - richard@nepr.agency.

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including over 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Read the full story at https://www.prweb.com/releases/catalent_to_discuss_the_future_of_cell_and_gene_therapy_manufacturing_at_world_orphan_drug_congress_europe/prweb16695271.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Catalent to Present Case Studies on Formulation Design for Early Phase Molecules and Discuss Benefits of Mass Spectrometry for HCP Analysis at AAPS PharmSci 360
2. Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board
3. Catalent to Launch OneBio Suite for Integrated Biologics Development, Manufacturing and Supply at BIO International 2019
4. Planning for Orphan Drug Supply to be Discussed by Catalent at World Orphan Drug Congress
5. Catalent Receives P&G External Business Partner of the Year Award
6. Biopharma Leaders to Discuss and Share Insights on the Regional Biopharma Ecosystem at LeadingBiotech’s NY/NJ CEO Conference
7. Biopharma Leaders Convene to Discuss Topics in Biotech, Healthcare and Innovation at LeadingBiotech’s Inaugural South CEO Conference
8. Greenberg Traurig Hosts Boston Healthcare Drinks and Discussion on China Biopharma Industry
9. Cell Signaling Technology Discusses Challenges and Opportunities of Post-translational Modifications and Data-Independent Acquisitions in Educational Webinar
10. DiaSorin Furthers the Discussion on HDV, the Most Severe Form of Viral Hepatitis, in Educational Webinar
11. STEM Initiatives in Grade School are Discussed on "On Demand" with Rob Lowe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2020)... ... ... Commercial launch readiness is a critical stage in a product life cycle. While ... global economic downturn will only increase price pressures overall for the industry. The era ... from every product launch is critical. However, history shows that only a third of ...
(Date:7/10/2020)... ... July 09, 2020 , ... Today CJ BIO announced the first ... insight on the “fifth taste” phenomenon that is revolutionizing ingredient mixes, nutritional content and ... be live on Monday, July 13, 2020 at11:00 AM (CDT) during SHIFT20, the virtual ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com , ... biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European Hematology ... Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase 1 ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., ... hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. ... Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of ...
(Date:7/7/2020)... BOSTON (PRWEB) , ... July 06, 2020 , ... ... Innovative Practices Awards. Entries from Roche, Eli Lilly, Bristol-Myers Squibb, the University of ... Since 2003, Bio-IT World has hosted an elite awards program, highlighting outstanding examples ...
(Date:7/1/2020)... ... June 29, 2020 , ... The Interlocal Purchasing ... to its membership, recently named BioFit Engineered Products an Awarded Vendor. ... purchase ergonomic seating, cafeteria tables, book trucks and carts at discounted pricing without ...
(Date:6/28/2020)... ... June 25, 2020 , ... The Indoor Lab, a leading provider of sensor ... of all types to ensure cleanliness, distancing and occupancy with its patent pending WipeAway™ ... enabled business will provide a health performance index system that scores all aspects of ...
Breaking Biology Technology: